{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:11:04Z","timestamp":1789020664903,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA225517"],"award-info":[{"award-number":["P01CA225517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA18029-41"],"award-info":[{"award-number":["P01CA18029-41"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Emmerson Collective, Immunotherapy Integrated Research Center Fred Hutchinson Cancer Center, Elevate Bio"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67446-5","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:52:41Z","timestamp":1767426761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A CD8\u03b1\u03b2 co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands"],"prefix":"10.1038","volume":"17","author":[{"given":"Shihong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2596-1872","authenticated-orcid":false,"given":"Tzu-Hao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin\u00e9ad","family":"Kinsella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mazziotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan S.","family":"McAfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariunaa","family":"Munkhbat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yapeng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5751-3881","authenticated-orcid":false,"given":"Valentin","family":"Voillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8327","authenticated-orcid":false,"given":"Colton W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menna","family":"Hailemariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Bakhtiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6799-2022","authenticated-orcid":false,"given":"Cecilia","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-6208","authenticated-orcid":false,"given":"Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1963-0884","authenticated-orcid":false,"given":"Alessandro M.","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6660-6257","authenticated-orcid":false,"given":"Daniel G.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Furiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phung","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon K.","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-6533","authenticated-orcid":false,"given":"Anthony","family":"Rongvaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3812-647X","authenticated-orcid":false,"given":"Phillip D.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0736-4195","authenticated-orcid":false,"given":"Thomas M.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-5448","authenticated-orcid":false,"given":"Aude G.","family":"Chapuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"67446_CR1","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","volume":"22","author":"CA Klebanoff","year":"2023","unstructured":"Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A. & Ribas, A. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nat. Rev. Drug Discov. 22, 996\u20131017 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"67446_CR2","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1158\/1535-7163.MCT-23-0310","volume":"23","author":"A Doug\u00e9","year":"2024","unstructured":"Doug\u00e9, A., El Ghazzi, N., Lemal, R. & Rouzaire, P. Adoptive T cell therapy in solid tumors: state-of-the art, current challenges, and upcoming improvements. Mol. Cancer Ther. 23, 272\u2013284 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"67446_CR3","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner, R. et al. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N. Engl. J. Med 386, 2112\u20132119 (2022).","journal-title":"N. Engl. J. Med"},{"key":"67446_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong, D. S. et al. Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial. Nat. Med 29, 104\u2013114 (2023).","journal-title":"Nat. Med"},{"key":"67446_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan, T., Zhu, L. & Chen, J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp. Hematol. Oncol. 12, 14 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"67446_CR6","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics 12, 6273\u20136290 (2022).","journal-title":"Theranostics"},{"key":"67446_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418527","volume":"15","author":"L Lopresti","year":"2024","unstructured":"Lopresti, L., Tatangelo, V., Baldari, C. T. & Patrussi, L. Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy. Front Immunol. 15, 1418527 (2024).","journal-title":"Front Immunol."},{"key":"67446_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail, M., Jiang, C. H. & Li, N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct. Target Ther. 10, 227 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"67446_CR9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"67446_CR10","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest"},{"key":"67446_CR11","doi-asserted-by":"publisher","first-page":"27491","DOI":"10.1074\/jbc.M500555200","volume":"280","author":"L Wooldridge","year":"2005","unstructured":"Wooldridge, L. et al. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J. Biol. Chem. 280, 27491\u201327501 (2005).","journal-title":"J. Biol. Chem."},{"key":"67446_CR12","doi-asserted-by":"publisher","first-page":"eabg8070","DOI":"10.1126\/scitranslmed.abg8070","volume":"14","author":"MC Lahman","year":"2022","unstructured":"Lahman, M. C. et al. Targeting an alternate Wilms\u2019 tumor antigen 1 peptide bypasses immunoproteasome dependency. Sci. Transl. Med 14, eabg8070 (2022).","journal-title":"Sci. Transl. Med"},{"key":"67446_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/CJI.0000000000000456","volume":"46","author":"VE Anderson","year":"2023","unstructured":"Anderson, V. E. et al. Enhancing efficacy of TCR-engineered CD4 + T cells via coexpression of CD8alpha. J. Immunother. 46, 132\u2013144 (2023).","journal-title":"J. Immunother."},{"key":"67446_CR14","doi-asserted-by":"publisher","unstructured":"Laletin, V., Bernard, P. L., Costa da Silva, C., Guittard, G. & Nunes, J. A. Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets. J. Immunother. Cancer 11 https:\/\/doi.org\/10.1136\/jitc-2022-005845 (2023).","DOI":"10.1136\/jitc-2022-005845"},{"key":"67446_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1600-065X.2009.00771.x","volume":"229","author":"G Driessens","year":"2009","unstructured":"Driessens, G., Kline, J. & Gajewski, T. F. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol. Rev. 229, 126\u2013144 (2009).","journal-title":"Immunol. Rev."},{"key":"67446_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218\u2013232 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"67446_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-065X.2009.00784.x","volume":"229","author":"AH Sharpe","year":"2009","unstructured":"Sharpe, A. H. Mechanisms of costimulation. Immunol. Rev. 229, 5\u201311 (2009).","journal-title":"Immunol. Rev."},{"key":"67446_CR18","doi-asserted-by":"publisher","unstructured":"Oda, S. K. et al. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. J. Exp. Med. 217 https:\/\/doi.org\/10.1084\/jem.20191166 (2020).","DOI":"10.1084\/jem.20191166"},{"key":"67446_CR19","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1182\/blood-2017-04-777052","volume":"130","author":"SK Oda","year":"2017","unstructured":"Oda, S. K. et al. A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. Blood 130, 2410\u20132419 (2017).","journal-title":"Blood"},{"key":"67446_CR20","doi-asserted-by":"publisher","unstructured":"Guo, J., Kent, A. & Davila, E. Chimeric non-antigen receptors in T cell-based cancer therapy. J. Immunother. Cancer 9 https:\/\/doi.org\/10.1136\/jitc-2021-002628 (2021).","DOI":"10.1136\/jitc-2021-002628"},{"key":"67446_CR21","first-page":"4072","volume":"61","author":"S Pascolo","year":"2001","unstructured":"Pascolo, S. et al. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res 61, 4072\u20134077 (2001).","journal-title":"Cancer Res"},{"key":"67446_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/0076-6879(93)18026-9","volume":"218","author":"MA Frohman","year":"1993","unstructured":"Frohman, M. A. Rapid amplification of complementary DNA ends for generation of full-length complementary DNAs: thermal RACE. Methods Enzymol. 218, 340\u2013356 (1993).","journal-title":"Methods Enzymol."},{"key":"67446_CR23","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis, A. G. et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat. Med 25, 1064\u20131072 (2019).","journal-title":"Nat. Med"},{"key":"67446_CR24","doi-asserted-by":"publisher","unstructured":"Davari, K. et al. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy. J. Immunother. Cancer 9 https:\/\/doi.org\/10.1136\/jitc-2020-002035 (2021).","DOI":"10.1136\/jitc-2020-002035"},{"key":"67446_CR25","doi-asserted-by":"publisher","unstructured":"Caballero, O. L. et al. Frequent MAGE mutations in human melanoma. PLoS One 5 https:\/\/doi.org\/10.1371\/journal.pone.0012773 (2010).","DOI":"10.1371\/journal.pone.0012773"},{"key":"67446_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"67446_CR27","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Q Zhou","year":"2011","unstructured":"Zhou, Q. et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117, 4501\u20134510 (2011).","journal-title":"Blood"},{"key":"67446_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1158\/0008-5472.CAN-16-2684","volume":"78","author":"FP Canale","year":"2018","unstructured":"Canale, F. P. et al. CD39 expression defines cell exhaustion in tumor-infiltrating CD8(+) T Cells. Cancer Res 78, 115\u2013128 (2018).","journal-title":"Cancer Res"},{"key":"67446_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1084\/jem.20130902","volume":"211","author":"D Liu","year":"2014","unstructured":"Liu, D. et al. 2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses. J. Exp. Med 211, 297\u2013311 (2014).","journal-title":"J. Exp. Med"},{"key":"67446_CR30","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A. & Bluestone, J. A. CD28 Costimulation: From Mechanism to Therapy. Immunity 44, 973\u2013988 (2016).","journal-title":"Immunity"},{"key":"67446_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/PPO.0000000000000032","volume":"20","author":"S Kakarla","year":"2014","unstructured":"Kakarla, S. & Gottschalk, S. CAR T cells for solid tumors: armed and ready to go?. Cancer J. 20, 151\u2013155 (2014).","journal-title":"Cancer J."},{"key":"67446_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34877-3","volume":"13","author":"C Zhang","year":"2022","unstructured":"Zhang, C. et al. A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. Nat. Commun. 13, 7250 (2022).","journal-title":"Nat. Commun."},{"key":"67446_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22801-0","volume":"12","author":"F Wu","year":"2021","unstructured":"Wu, F. et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat. Commun. 12, 2540 (2021).","journal-title":"Nat. Commun."},{"key":"67446_CR34","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","volume":"64","author":"BA Irving","year":"1991","unstructured":"Irving, B. A. & Weiss, A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891\u2013901 (1991).","journal-title":"Cell"},{"key":"67446_CR35","doi-asserted-by":"publisher","first-page":"7049","DOI":"10.1158\/0008-5472.CAN-17-0653","volume":"77","author":"S Kaczanowska","year":"2017","unstructured":"Kaczanowska, S. et al. A synthetic CD8 alpha:MyD88 coreceptor enhances CD8(+) T-cell responses to weakly immunogenic and lowly expressed tumor antigens. Cancer Res. 77, 7049\u20137058 (2017).","journal-title":"Cancer Res"},{"key":"67446_CR36","first-page":"3392","volume":"14","author":"PH Stein","year":"1994","unstructured":"Stein, P. H., Fraser, J. D. & Weiss, A. The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3\u2019-kinase. Mol. Cell Biol. 14, 3392\u20133402 (1994).","journal-title":"Mol. Cell Biol."},{"key":"67446_CR37","doi-asserted-by":"publisher","first-page":"913","DOI":"10.4049\/jimmunol.170.2.913","volume":"170","author":"R Fragoso","year":"2003","unstructured":"Fragoso, R. et al. Lipid raft distribution of CD4 depends on its palmitoylation and association with Lck, and evidence for CD4-induced lipid raft aggregation as an additional mechanism to enhance CD3 signaling. J. Immunol. 170, 913\u2013921 (2003).","journal-title":"J. Immunol."},{"key":"67446_CR38","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s12276-020-0435-8","volume":"52","author":"JR Hwang","year":"2020","unstructured":"Hwang, J. R., Byeon, Y., Kim, D. & Park, S. G. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. Exp. Mol. Med 52, 750\u2013761 (2020).","journal-title":"Exp. Mol. Med"},{"key":"67446_CR39","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/embor.2011.209","volume":"12","author":"V Rybakin","year":"2011","unstructured":"Rybakin, V., Clamme, J. P., Ampudia, J., Yachi, P. P. & Gascoigne, N. R. CD8\u03b1\u03b1 and -\u03b1\u03b2 isotypes are equally recruited to the immunological synapse through their ability to bind to MHC class I. EMBO Rep. 12, 1251\u20131256 (2011).","journal-title":"EMBO Rep."},{"key":"67446_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2567.2012.03625.x","volume":"137","author":"DK Cole","year":"2012","unstructured":"Cole, D. K. et al. The molecular determinants of CD8 co-receptor function. Immunology 137, 139\u2013148 (2012).","journal-title":"Immunology"},{"key":"67446_CR41","doi-asserted-by":"publisher","first-page":"107906","DOI":"10.1016\/j.intimp.2021.107906","volume":"98","author":"F Sun","year":"2021","unstructured":"Sun, F. et al. The MAPK dual specific phosphatase (DUSP) proteins: A versatile wrestler in T cell functionality. Int Immunopharmacol. 98, 107906 (2021).","journal-title":"Int Immunopharmacol."},{"key":"67446_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller, N., Anderson, A. C. & Kuchroo, V. K. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity 57, 206\u2013222 (2024).","journal-title":"Immunity"},{"key":"67446_CR43","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Investig. 124, 2246\u20132259 (2014).","journal-title":"J. Clin. Investig."},{"key":"67446_CR44","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1097\/CJI.0b013e3181fad2b0","volume":"33","author":"T Inozume","year":"2010","unstructured":"Inozume, T. et al. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J. Immunother. 33, 956\u2013964 (2010).","journal-title":"J. Immunother."},{"key":"67446_CR45","doi-asserted-by":"publisher","first-page":"105240","DOI":"10.1016\/j.ebiom.2024.105240","volume":"106","author":"J Mietz","year":"2024","unstructured":"Mietz, J. et al. Human effector CD8(+) T cells with an activated and exhausted-like phenotype control tumour growth in vivo in a humanized tumour model. EBioMedicine 106, 105240 (2024).","journal-title":"EBioMedicine"},{"key":"67446_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/2326-6066.CIR-20-0253","volume":"9","author":"JC Boucher","year":"2021","unstructured":"Boucher, J. C. et al. CD28 costimulatory domain-targeted mutations enhance chimeric antigen receptor t-cell function. Cancer Immunol. Res 9, 62\u201374 (2021).","journal-title":"Cancer Immunol. Res"},{"key":"67446_CR47","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1172\/JCI133215","volume":"130","author":"S Guedan","year":"2020","unstructured":"Guedan, S. et al. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. J. Clin. Invest 130, 3087\u20133097 (2020).","journal-title":"J. Clin. Invest"},{"key":"67446_CR48","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1182\/blood-2003-04-1255","volume":"102","author":"P Nguyen","year":"2003","unstructured":"Nguyen, P., Moisini, I. & Geiger, T. L. Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function. Blood 102, 4320\u20134325 (2003).","journal-title":"Blood"},{"key":"67446_CR49","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/mt.2011.9","volume":"19","author":"DM Kofler","year":"2011","unstructured":"Kofler, D. M. et al. CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. Mol. Ther. 19, 760\u2013767 (2011).","journal-title":"Mol. Ther."},{"key":"67446_CR50","doi-asserted-by":"publisher","first-page":"43114","DOI":"10.18632\/oncotarget.17810","volume":"8","author":"TCJ Tortelli","year":"2017","unstructured":"Tortelli, T. C. J. et al. Accumulation of prohibitin is a common cellular response to different stressing stimuli and protects melanoma cells from ER stress and chemotherapy-induced cell death. Oncotarget 8, 43114\u201343129 (2017).","journal-title":"Oncotarget"},{"key":"67446_CR51","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1073\/pnas.1017340108","volume":"108","author":"K Adachi","year":"2011","unstructured":"Adachi, K. & Davis, M. M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells. Proc. Natl. Acad. Sci. USA 108, 1549\u20131554 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67446_CR52","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s00432-022-04547-4","volume":"149","author":"K Drougkas","year":"2023","unstructured":"Drougkas, K. et al. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?. J. Cancer Res Clin. Oncol. 149, 2709\u20132734 (2023).","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"67446_CR53","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1093\/oncolo\/oyad078","volume":"28","author":"R Yarza","year":"2023","unstructured":"Yarza, R. et al. Efficacy of T-cell receptor-based adoptive cell therapy in cutaneous melanoma: a meta-analysis. Oncologist 28, e406\u2013e415 (2023).","journal-title":"Oncologist"},{"key":"67446_CR54","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/2326-6066.CIR-22-0444","volume":"11","author":"AM Tsimberidou","year":"2023","unstructured":"Tsimberidou, A. M. et al. Feasibility and safety of personalized, multi-target, adoptive cell therapy (ima101): first-in-human clinical trial in patients with advanced metastatic cancer. Cancer Immunol. Res. 11, 925\u2013945 (2023).","journal-title":"Cancer Immunol. Res"},{"key":"67446_CR55","doi-asserted-by":"publisher","first-page":"908","DOI":"10.4161\/onci.21205","volume":"1","author":"J Thibodeau","year":"2012","unstructured":"Thibodeau, J., Bourgeois-Daigneault, M. C. & Lapointe, R. Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology 1, 908\u2013916 (2012).","journal-title":"Oncoimmunology"},{"key":"67446_CR56","doi-asserted-by":"publisher","first-page":"7698","DOI":"10.4049\/jimmunol.177.11.7698","volume":"177","author":"MP Ndejembi","year":"2006","unstructured":"Ndejembi, M. P. et al. Control of memory CD4 T cell recall by the CD28\/B7 costimulatory pathway. J. Immunol. 177, 7698\u20137706 (2006).","journal-title":"J. Immunol."},{"key":"67446_CR57","doi-asserted-by":"publisher","unstructured":"Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal 11 https:\/\/doi.org\/10.1126\/scisignal.aat6753 (2018).","DOI":"10.1126\/scisignal.aat6753"},{"key":"67446_CR58","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1002\/eji.1830271006","volume":"27","author":"RV Parry","year":"1997","unstructured":"Parry, R. V. et al. Ligation of the T cell co-stimulatory receptor CD28 activates the serine-threonine protein kinase protein kinase B. Eur. J. Immunol. 27, 2495\u20132501 (1997).","journal-title":"Eur. J. Immunol."},{"key":"67446_CR59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1084\/jem.190.3.375","volume":"190","author":"AD Holdorf","year":"1999","unstructured":"Holdorf, A. D. et al. Proline residues in CD28 and the Src homology (SH)3 domain of Lck are required for T cell costimulation. J. Exp. Med 190, 375\u2013384 (1999).","journal-title":"J. Exp. Med"},{"key":"67446_CR60","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.4049\/jimmunol.1301240","volume":"192","author":"JS Boomer","year":"2014","unstructured":"Boomer, J. S., Deppong, C. M., Shah, D. D., Bricker, T. L. & Green, J. M. Cutting edge: A double-mutant knockin of the CD28 YMNM and PYAP motifs reveals a critical role for the YMNM motif in regulation of T cell proliferation and Bcl-xL expression. J. Immunol. 192, 3465\u20133469 (2014).","journal-title":"J. Immunol."},{"key":"67446_CR61","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1002\/eji.200838223","volume":"38","author":"T Gogishvili","year":"2008","unstructured":"Gogishvili, T. et al. Proliferative signals mediated by CD28 superagonists require the exchange factor Vav1 but not phosphoinositide 3-kinase in primary peripheral T cells. Eur. J. Immunol. 38, 2528\u20132533 (2008).","journal-title":"Eur. J. Immunol."},{"key":"67446_CR62","doi-asserted-by":"publisher","first-page":"iqad006","DOI":"10.1093\/oxfimm\/iqad006","volume":"4","author":"E Jenkins","year":"2023","unstructured":"Jenkins, E., Whitehead, T., Fellermeyer, M., Davis, S. J. & Sharma, S. The current state and future of T-cell exhaustion research. Oxf. Open Immunol. 4, iqad006 (2023).","journal-title":"Oxf. Open Immunol."},{"key":"67446_CR63","doi-asserted-by":"publisher","unstructured":"Chiorazzi, M. et al. Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment. J. Immunother. Cancer 11 https:\/\/doi.org\/10.1136\/jitc-2023-006921 (2023).","DOI":"10.1136\/jitc-2023-006921"},{"key":"67446_CR64","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nbt.2858","volume":"32","author":"A Rongvaux","year":"2014","unstructured":"Rongvaux, A. et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32, 364\u2013372 (2014).","journal-title":"Nat. Biotechnol."},{"key":"67446_CR65","doi-asserted-by":"publisher","first-page":"174ra127","DOI":"10.1126\/scitranslmed.3004916","volume":"5","author":"AG Chapuis","year":"2013","unstructured":"Chapuis, A. G. et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci. Transl. Med. 5, 174ra127 (2013).","journal-title":"Sci. Transl. Med"},{"key":"67446_CR66","doi-asserted-by":"publisher","first-page":"A51","DOI":"10.1158\/2326-6074.TUMIMM17-A51","volume":"6","author":"TM Schmitt","year":"2018","unstructured":"Schmitt, T. M. et al. Abstract A51: High-throughput method identifies rare, high-affinity, thymus-vetted T cell receptors (TCRs) for clinical translation. Cancer Immunol. Res. 6, A51\u2013A51 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"67446_CR67","unstructured":"National Cancer Institute, N. I. o. H. (Cancer Therapy Evaluation Program, 2009)."},{"key":"67446_CR68","doi-asserted-by":"publisher","first-page":"17608","DOI":"10.18632\/oncotarget.24807","volume":"9","author":"S Rosskopf","year":"2018","unstructured":"Rosskopf, S. et al. A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies. Oncotarget 9, 17608\u201317619 (2018).","journal-title":"Oncotarget"},{"key":"67446_CR69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13059-019-1662-y","volume":"20","author":"ATL Lun","year":"2019","unstructured":"Lun, A. T. L. et al. EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. Genome Biol. 20, 63\u201363 (2019).","journal-title":"Genome Biol."},{"key":"67446_CR70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67446-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67446-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67446-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:07:04Z","timestamp":1769220424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67446-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67446"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67446-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5939098\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.G.C. has received support from Elevate Bio, Juno Therapeutics, Lonza, and Affini-T. P.D.G. is on the Scientific Advisory Board of Celsius, Earli, Elpiscience, Immunoscape, Rapt, and Nextech, was a scientific founder of Juno Therapeutics, and receives research support from Lonza. A.G.C., T.M.S., and P.D.G. are co-founders of, have equity in, and receive research support from Affini-T. A.G.C., T.M.S., and M.M. are listed as inventors on patents related to MA1 TCR and CD8\/28 constructs. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"753"}}